{
    "nctId": "NCT00023790",
    "briefTitle": "Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin",
    "officialTitle": "Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "Toxicity as assessed by physical exam and laboratory data.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed tumor for which no potential curative therapy exists (e.g., surgery, radiotherapy, or systemic chemotherapy)\n\n  * The following tumor types are eligible:\n\n    * Cutaneous nodular metastatic breast carcinoma lesion with loco-regional cutaneous, soft tissue, or chest wall involvement\n\n      * No chest wall recurrence without prior radiotherapy\n      * Other metastatic sites allowed provided patient is concurrently receiving hormonal therapy or trastuzumab (Herceptin) of at least 4 weeks duration\n    * Cutaneous or superficial subcutaneous nodular metastatic head and neck lesion\n    * Cutaneous nodular Kaposi's sarcoma lesion\n    * Stage IA-IIB or IVA cutaneous T-cell lymphoma (CTCL)\n\n      * CTCL patches, plaques, or tumors with a surface area of up to 25 cm\\^2 if other areas of involved skin are blocked from therapy\n    * Squamous cell or basal cell carcinoma of the skin that is not eligible for standard therapy (e.g., cryosurgery, radiotherapy, electrodesiccation and curettage, or excision)\n    * Cutaneous and subcutaneous metastasis from any solid tumor (e.g., thoracic, gastrointestinal, or genitourinary cancers or sarcomas)\n* Bidimensionally measurable disease\n\n  * No more than 2 lesions may be treated\n* No single area greater than 36 cm\\^2 may be treated (maximum of 25 cm\\^2 tumor mass with a 1 cm margin)\n* Tumor treatable by surface (non-contact) light illumination\n* Skin type I-III\n* No tumors of the eyelids\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Male or female\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* ECOG 0-2\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Hemoglobin at least 9 g/dL\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin no greater than 1.5 mg/dL\n* AST/ALT no greater than 2 times upper limit of normal (ULN)\n* Alkaline phosphatase no greater than 2 times ULN\n* No history of hepatic cirrhosis\n* No hepatic disease requiring therapy\n\nRenal:\n\n* Creatinine no greater than 2.0 mg/dL OR\n* Creatinine clearance at least 50 mL/min\n* No renal disease requiring therapy\n\nCardiovascular:\n\n* No myocardial infarction within the past 6 months\n* No significant congestive heart failure requiring therapy\n* No peripheral vascular disease\n\nOther:\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Antinuclear antibody negative\n* No sepsis\n* No prior allergic or hypersensitivity reaction to paclitaxel vehicle\n* No known photosensitivity diseases such as porphyria, systemic lupus erythematosus, xeroderma pigmentosum, or polymorphous light eruption\n* No symptomatic collagen vascular disease\n* Insulin-dependent or adult-onset diabetes mellitus allowed provided there are no lower extremity lesions\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* See Disease Characteristics\n* At least 4 weeks since prior immunotherapy\n* No concurrent immunotherapy\n\nChemotherapy:\n\n* See Disease Characteristics\n* At least 4 weeks since prior systemic chemotherapy\n* No concurrent chemotherapy\n\nEndocrine therapy:\n\n* See Disease Characteristics\n* No concurrent corticosteroids\n\nRadiotherapy:\n\n* See Disease Characteristics\n* More than 4 weeks since prior radiotherapy\n* More than 4 weeks since prior ultraviolet B light therapy or psoralen-ultraviolet light therapy to non-study lesions/areas\n* No concurrent radiotherapy\n\nSurgery:\n\n* See Disease Characteristics\n\nOther:\n\n* At least 5 days since prior warfarin\n* At least 4 weeks since prior investigational drugs\n* At least 4 weeks since prior local therapy to study lesions\n* At least 6 months since prior photodynamic therapy\n* No concurrent aspirin, aspirin-containing medications, or non-steroidal anti-inflammatory drugs (e.g., ibuprofen, indomethacin, or cyclo-oxygenase \\[COX\\]-1 and COX-2 inhibitors)\n* No other concurrent photosensitizing medications such as tetracyclines, psoralens, nalidixic acid, griseofulvin, sulfa drugs, hydrochlorothiazide, furosemide, phenothiazines, or amiodarone\n* No concurrent therapeutic dosages of warfarin (non-therapeutic dosages allowed)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}